KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Accumulated Expenses (2016 - 2019)

Historic Accumulated Expenses for Biomarin Pharmaceutical (BMRN) over the last 10 years, with Q1 2019 value amounting to $87.3 million.

  • Biomarin Pharmaceutical's Accumulated Expenses rose 1391.64% to $87.3 million in Q1 2019 from the same period last year, while for Mar 2019 it was $87.3 million, marking a year-over-year increase of 1391.64%. This contributed to the annual value of $149.9 million for FY2018, which is 650.37% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Accumulated Expenses stood at $87.3 million for Q1 2019, which was up 1391.64% from $149.9 million recorded in Q4 2018.
  • Over the past 5 years, Biomarin Pharmaceutical's Accumulated Expenses peaked at $149.9 million during Q4 2018, and registered a low of $45.0 million during Q1 2016.
  • Its 5-year average for Accumulated Expenses is $92.2 million, with a median of $95.0 million in 2018.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Accumulated Expenses skyrocketed by 10964.62% in 2015 and then tumbled by 5770.23% in 2016.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Accumulated Expenses stood at $95.3 million in 2015, then grew by 14.36% to $109.0 million in 2016, then grew by 29.11% to $140.8 million in 2017, then rose by 6.5% to $149.9 million in 2018, then crashed by 41.8% to $87.3 million in 2019.
  • Its Accumulated Expenses stands at $87.3 million for Q1 2019, versus $149.9 million for Q4 2018 and $114.5 million for Q3 2018.